Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 8.8% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals Inc. (REGN) is a leading biotechnology company recognized for its innovative therapies, including Dupixent and Eylea, with a focus on developing treatments for various medical conditions, driving revenue growth and market performance.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 8.8% on Apr 29, 2026 18:01

• Regeneron posted strong Q1 2026 results demonstrating robust revenue growth fueled by Dupixent's success, highlighting the company's commitment to innovation and market positioning.
• Despite surpassing earnings expectations and unveiling a new $3 billion share repurchase program, the stock faced a significant decline, potentially tied to concerns about reduced sales in its eye care therapy Eylea.
• Market fluctuations or possible profit-taking by investors may have influenced the stock's downward trajectory, overshadowing positive financial news and strategic initiatives by the company.
• Analysts maintain a positive outlook on Regeneron, focusing on its growth prospects and ongoing pipeline developments, suggesting a potential recovery in the future.

REGN Price Chart

REGN Technical Analysis

REGN News

Cooper Companies stock hits 52-week low at 61.76 USD

Cooper Companies (COO) recently hit a 52-week low of $61.76, marking a 23% year-to-date decline, although InvestingPro data suggests the stock is undervalued and in oversold territory, with management aggressively buying back shares. Despite this downturn, the company reported strong Q1 fiscal 2026 earnings, surpassing expectations and raising full-year guidance, leading analysts like Needham and Barclays to increase their price targets. These positive financial and strategic developments indicate potential for recovery despite current market pressures.

https://www.investing.com/news/company-news/cooper-companies-stock-hits-52week-low-at-6176-usd-93CH-4645856

Regeneron shares slide despite Q1 beat

Regeneron Pharmaceuticals Inc. shares fell more than 5.5% despite the drugmaker reporting better-than-expected first-quarter results and announcing a new $3 billion share repurchase program. While revenue and adjusted earnings topped Wall Street forecasts, driven by strong Dupixent sales, a significant decline in its eye care therapy Eylea negatively impacted results and led to a trimmed GAAP gross margin outlook.

https://ca.finance.yahoo.com/news/regeneron-shares-slide-despite-q1-141200998.html

Regeneron Pharmaceuticals Delivers 19% Revenue Growth in Q1 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong Q1 2026 results, with non-GAAP earnings of $9.47 per share, beating consensus estimates, and a 19.0% year-over-year revenue increase to $3.61 billion. The growth was significantly driven by its blockbuster drug Dupixent, which saw a 33.0% increase in revenue. Despite a 6.5% drop in stock price following the announcement, analyst sentiment remains positive, with 19 buy ratings and no sell recommendations.

https://news.alphastreet.com/regeneron-pharmaceuticals-delivers-19-revenue-growth-in-q1-2026/

Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips

Regeneron Pharmaceuticals Inc. reported strong Q1 2026 financial results, surpassing both EPS and revenue estimates, driven by collaborations with Sanofi and Bayer and key product performance. Despite the earnings beat, the stock experienced a pre-market dip, which the company attributes to broader market volatility or investor profit-taking. Regeneron also announced a new $3 billion share repurchase program and highlighted pipeline advancements in areas like genetic hearing loss, complement-mediated diseases, obesity, and oncology.

https://www.investing.com/news/transcripts/earnings-call-transcript-regeneron-q1-2026-beats-estimates-stock-dips-93CH-4645585

Regeneron drops despite Q1 beat, $3B share buyback program

Regeneron Pharmaceuticals reported a strong first quarter, beating both earnings and revenue expectations, and announced a new $3 billion share buyback program. Despite this positive financial news, the company's stock experienced a slight decline in early trading. The article is hosted on MSN.

https://www.msn.com/en-us/money/topstocks/regeneron-drops-despite-q1-beat-3b-share-buyback-program/ar-AA220Lmh?ocid=finance-verthp-feeds

Trending Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Aave ($AAVE) Crypto Forecast: Down 5.8% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.8% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.1% Today

Solana ($SOL) Crypto Forecast: Down 5.9% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Sonos Inc. ($SONO) Stock Forecast: Up 5.2% Today

HP Inc. ($HPQ) Stock Forecast: Up 15.6% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.2% Today

Regeneron Pharmaceuticals Inc. Price History

13.00.2026 - REGN Stock was down 5.4%

• A notable investor, PKO Investment Management Joint Stock Co, reduced its stake in Regeneron Pharmaceuticals by 40.4%, potentially sparking concerns among investors and contributing to the stock sell-off.
• The focus on AbbVie's MFN drug pricing agreement and US R&D commitment may have diverted attention from Regeneron, impacting its stock negatively.
• Raymond James increased Regeneron's price target to $820 from $800, displaying long-term confidence in the company, although short-term profit-taking behavior could have influenced the immediate market reaction.
• Strong financial performance and favorable analyst recommendations support an optimistic outlook on Regeneron, suggesting that the recent bearish movement might be a temporary decline amidst overall positive sentiment towards the company.

02.11.2025 - REGN Stock was down 5.7%

• The bearish movement in REGN's stock today can be attributed to Quadrant Capital Group LLC selling 688 shares, reducing its stake in the company by 25.6%. This sell-off might have created a negative sentiment among investors, leading to a decline in the stock price.
• Despite surpassing earnings expectations and maintaining strong profitability, REGN's stock underperformed on a day when the overall market, as represented by the S&P 500 Index and Dow Jones Industrial Average, also experienced losses. This broader market trend could have contributed to the downward pressure on REGN's stock.
• The partnership with Tessera Therapeutics to develop a gene-editing therapy for a rare disorder highlights REGN's commitment to innovation. However, heightened competition and potential regulatory delays mentioned in recent sources may have raised concerns among investors, impacting the stock price negatively.
• The overall positive outlook on REGN, with analysts rating it a "Moderate Buy" and the company announcing a quarterly dividend, suggests that the bearish movement today could be a short-term correction amidst a backdrop of long-term growth potential.

05.01.2026 - REGN Stock was down 0.4%

• The bearish movement in Regeneron's stock could be attributed to the overall negative sentiment surrounding the biotech sector, as highlighted by concerns over gene therapy safety issues at Sarepta Therapeutics and the competitive landscape.
• The selling of Ocular Therapeutix stock by its COO amidst a significant price drop and concerns about overvaluation in the sector may have added to the bearish pressure on biotech stocks, including Regeneron.
• Comments on Moderna and preference for other pharma and biotech names, particularly mentioning Regeneron as a more favorable option, could have influenced investor sentiment and contributed to the downward movement in Regeneron's stock price.
• The overall market perception of biotech companies may have led to profit-taking and a shift in investment focus away from companies like Regeneron, impacting its stock performance negatively.

24.03.2026 - REGN Stock was down 3.1%

• A decrease in the price target for REGN to $913 from $921 by Bernstein SocGen, while maintaining an Outperform rating, potentially influenced the bearish trend, hinting at a downside.
• Despite M&T Bank Corp increasing its stake by 193.9% and positive developments including FDA approval of a gene therapy, concerns about near-term revenue limitations seemed to outweigh the positive news, contributing to the bearish sentiment.
• Although analysis indicated REGN might be undervalued and positive factors like tariff relief and dividend increment were present, the prevailing market sentiment eclipsed these, resulting in the bearish movement.
• The reduction of stake by China Universal Asset Management Co. Ltd. by 7.5%, contrasted with positive developments and an earnings beat, likely intensified selling pressure on the stock, further fueling the bearish movement.

11.11.2025 - REGN Stock was up 5.6%

• Intact Investment Management Inc. significantly increasing its stake in REGN indicates growing confidence in the company's future prospects, potentially contributing to the bullish movement.
• Positive early data on Regeneron's Lynozyfic monotherapy for multiple myeloma patients showcases the company's promising developments in the oncology sector, boosting investor sentiment.
• Increasing the price target for REGN reflects optimism in the company's performance, aligning with the overall bullish trend in the market.
• The strong performance of AbbVie and Genmab's Epkinly at the ASH Annual Meeting may have positively influenced the biotech sector as a whole, indirectly benefiting companies like Regeneron.

29.03.2026 - REGN Stock was down 8.4%

• Regeneron surpassed Q1 2026 earnings and revenue estimates but saw a decline in its stock price, potentially linked to market volatility or profit-taking actions.
• The 5.5% decrease in Regeneron's shares could be linked to a 12% global revenue drop in its eye care therapy Eylea and a revised GAAP gross margin forecast, causing investor apprehension.
• Investors' reaction to Regeneron's positive financial results emphasizes the significance of not just meeting but surpassing market expectations to maintain stock performance.
• The stock's bearish movement despite strong financial performance illustrates the unpredictable nature of the stock market, where factors other than fundamental metrics can sway investor sentiment and stock values.

29.03.2026 - REGN Stock was down 7.5%

• REGN exceeded profit and revenue estimates in the latest quarter mainly due to the strong demand for Dupixent and Libtayo.
• Competitive pressures on its eye drug, Eylea, and production interruptions at its Limerick facility negatively impacted market sentiment.
• Insider selling and stake reductions by institutional players like Mitsubishi UFJ Trust & Banking Corp likely contributed to the stock's decline.
• The bearish movement in REGN today could have been influenced by market expectations surrounding earnings reports from tech giants such as Alphabet, Microsoft, Amazon, and Meta.

29.03.2026 - REGN Stock was down 8.8%

• Regeneron posted strong Q1 2026 results demonstrating robust revenue growth fueled by Dupixent's success, highlighting the company's commitment to innovation and market positioning.
• Despite surpassing earnings expectations and unveiling a new $3 billion share repurchase program, the stock faced a significant decline, potentially tied to concerns about reduced sales in its eye care therapy Eylea.
• Market fluctuations or possible profit-taking by investors may have influenced the stock's downward trajectory, overshadowing positive financial news and strategic initiatives by the company.
• Analysts maintain a positive outlook on Regeneron, focusing on its growth prospects and ongoing pipeline developments, suggesting a potential recovery in the future.

07.00.2026 - REGN Stock was up 5.2%

• Regeneron's stock rose by 2.9% following an upgrade in its rating to 'Buy' by Bank of America Securities, which also raised the price target to $860. A similar upgrade came from Citi, setting a price target of $900. These positive evaluations by analysts boosted confidence among investors regarding the company's future outlook.
• Merit Financial Group LLC notably increased its stake in Regeneron during the third quarter, indicating strong financial performance that surpassed analyst projections. This move further contributed to the overall positive trend in the company's stock value.
• The projected growth in the Diabetic Macular Edema (DME) market, where Regeneron holds a significant position, also added to the favorable prospects for the company. Forecasts suggest that the market for DME could reach US$ 7.44 billion by 2033, driven by advancements in retinal therapies. This anticipated growth aligns well with Regeneron's standing in the industry.